Literature DB >> 18830926

NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells.

Dwaine F Emerich1, Christopher G Thanos.   

Abstract

Neurotech Pharmaceuticals Inc is developing NT-501, an implantable polymeric device containing a genetically modified cell line that secretes ciliary neurotrophic factor, for the potential treatment of retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Phase III clinical trials for RP and a phase II clinical trial for dry AMD are ongoing. A phase I clinical trial showed that NT-501 treatment was well tolerated with variable, but positive improvements in visual acuity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18830926

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  22 in total

Review 1.  Biodegradable implants for sustained drug release in the eye.

Authors:  Susan S Lee; Patrick Hughes; Aron D Ross; Michael R Robinson
Journal:  Pharm Res       Date:  2010-06-10       Impact factor: 4.200

Review 2.  Advances in ocular drug delivery systems.

Authors:  Jennifer J Kang-Mieler; Kayla M Rudeen; Wenqiang Liu; William F Mieler
Journal:  Eye (Lond)       Date:  2020-02-18       Impact factor: 3.775

Review 3.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

Review 4.  The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms.

Authors:  Hannah Harvey; Szonya Durant
Journal:  Exp Brain Res       Date:  2014-09-03       Impact factor: 1.972

5.  Corneal endothelial autocrine VIP enhances its integrity in stored human donor corneoscleral explant.

Authors:  Shay-Whey M Koh; Dante Gloria; Joseph Molloy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

Review 6.  Dry age-related macular degeneration: A currently unmet clinical need.

Authors:  Jean-François Girmens; José-Alain Sahel; Katia Marazova
Journal:  Intractable Rare Dis Res       Date:  2012-08

Review 7.  Corneal endothelial autocrine trophic factor VIP in a mechanism-based strategy to enhance human donor cornea preservation for transplantation.

Authors:  Shay-Whey Margaret Koh
Journal:  Exp Eye Res       Date:  2011-10-25       Impact factor: 3.467

Review 8.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

9.  Stanniocalcin-1 rescued photoreceptor degeneration in two rat models of inherited retinal degeneration.

Authors:  Gavin W Roddy; Robert H Rosa; Joo Youn Oh; Joni H Ylostalo; Thomas J Bartosh; Hosoon Choi; Ryang Hwa Lee; Douglas Yasumura; Kelly Ahern; Gregory Nielsen; Michael T Matthes; Matthew M LaVail; Darwin J Prockop
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

10.  Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.

Authors:  Kevin Gregory-Evans; Francis Chang; Matthew D Hodges; Cheryl Y Gregory-Evans
Journal:  Mol Vis       Date:  2009-05-13       Impact factor: 2.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.